BEIJING – Despite previous expectations of deep price discounts, the results of China's first ever national negotiations for costly drugs included in reimbursement schemes have still surprised many.
The outcomes, announced on May 20, saw a further big price cut for hepatitis B treatment Viread (tenofovir), developed by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?